Compound Guide
NAD+ Research — Nicotinamide Adenine Dinucleotide, Aging & Cellular Metabolism
Editorial Standards
Avera Refined Wellness holds its research journal content to a standard requiring specific research claims to reference published, peer-reviewed sources — not general assertions. We are in the process of auditing and updating existing journal content to consistently meet this standard.
NAD+ research: coenzyme for sirtuins, PARPs, mitochondria declining with age. Human NMN trial 2022 (PMC9036060). DNA repair and aging.
All products are supplied strictly for in-vitro laboratory research use only by qualified professionals. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
NAD⁺ (nicotinamide adenine dinucleotide) is present in every living cell, participating in hundreds of metabolic reactions as an electron carrier and as the obligate substrate for sirtuins (epigenetic regulation), PARPs (DNA damage repair), and CD38 (immune and calcium signaling). NAD⁺ levels decline measurably with age across all mammalian species studied, linked to impaired DNA repair, reduced mitochondrial biogenesis, metabolic dysfunction, and accelerated cellular aging.
Age-Related Decline
A study (PMC3407129, 2012) documented NAD⁺ reduction in multiple human tissue types with age, with reduced PARP activity and increased DNA damage markers. The resulting cycle: aging → NAD⁺ decline → reduced sirtuin and PARP activity → impaired DNA repair → further tissue dysfunction.
Lower NAD⁺ has been correlated in the literature with obesity, diabetes, heart failure, atherosclerosis, myocardial ischemia, cognitive decline, and neurodegenerative conditions.
NMN Human Clinical Trial (2022)
A randomized, double-blind, placebo-controlled trial (Yamamoto T et al., Nutrients, 2022, PMC9036060) enrolled 30 healthy subjects and confirmed oral NMN administration safely and significantly increased blood NAD⁺ in a dose-dependent manner over 12 weeks.
Cardiovascular Research
A 2024 systematic review (PMC11394709) summarized evidence that NMN attenuates development of heart failure, atherosclerosis, and myocardial ischemia/reperfusion injury in in vivo and in vitro models.
Neurological Research
NAD⁺ repletion via NMN in aged mice maintained neural progenitor cell populations, reduced neuronal death, and improved cognitive function in Alzheimer's disease models (PMC10917541). Yoshino M et al. (Science. 2021;372(6547):1224–1229) demonstrated NMN increased muscle insulin sensitivity in prediabetic women in a randomized controlled trial.
Key References
- Gomes AP, et al. Declining NAD⁺ induces a pseudohypoxic state. Cell. 2013;155(7):1624–1638.
- Yamamoto T, et al. Oral NMN is safe and increases blood NAD⁺. Nutrients. 2022. PMC9036060.
- Covarrubias AJ, et al. NAD⁺ metabolism and its roles in cellular processes. Nat Rev Mol Cell Biol. 2021;22(2):119–141.
- Yoshino M, et al. NMN increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229.
For educational and research reference only. NAD+ is supplied for in-vitro laboratory research use only. Not for human consumption.
Research Disclaimer: All content published in the Avera Research Journal is provided for informational and scientific discussion purposes only. It does not constitute medical advice, treatment guidance, or a recommendation for human use of any compound. All Avera products are supplied exclusively for in-vitro laboratory research by qualified professionals. Not FDA-evaluated. Not for human consumption.
This article is for informational and research purposes only. All compounds referenced are sold strictly for in-vitro laboratory research use and are not intended for human consumption, veterinary use, or clinical/diagnostic procedures. These statements have not been evaluated by the FDA. Avera Refined Wellness is a subsidiary of RDS 412 LLC.
Related Research